Sterol composition of Pneumocystis jirovecii with blocked 14alpha-demethylase activity

José-Luis Giner1, Hui Zhao, Zunika Amit

  • 1Department of Chemistry, State University of New York-ESF, Syracuse, NY 13210, USA. jlginer@syr.edu

Insights

Pneumocystis jirovecii, a fungus causing lung infections, synthesizes unique sterols. This study reveals a blockage in sterol 14alpha-demethylase, impacting fungal sterol synthesis and potentially explaining treatment resistance.

Area of Science:

  • Fungal biochemistry
  • Medical mycology
  • Molecular biology

Background:

  • Antifungal drugs targeting sterol synthesis are common but ineffective against Pneumocystis jirovecii.
  • P. jirovecii synthesizes unique C28 and C29 24-alkylsterols, lacking ergosterol.
  • Two distinct sterol phenotypes exist in P. jirovecii.

Purpose of the Study:

  • To elucidate the sterol composition of P. jirovecii from a human lung specimen.
  • To investigate the functional status of key enzymes in P. jirovecii sterol biosynthesis.

Main Methods:

  • Nuclear magnetic resonance (NMR) analysis of sterols.
  • Characterization of sterol molecular species from a human lung P. jirovecii specimen.

Main Results:

  • 28 sterol molecular species were identified, with 15 having a methyl group at C-14 (96% of total sterol mass).
  • This indicates a blockage in sterol 14alpha-demethylase activity.
  • 24 of the 28 sterols were 24-alkylated, showing functional S-adenosyl-L-methionine:sterol C-24 methyl transferase.

Conclusions:

  • The findings suggest a sterol 14alpha-demethylase block in this P. jirovecii phenotype.
  • The C-24 methyltransferase activity remains functional.
  • Understanding these sterol pathways may inform new therapeutic strategies against P. jirovecii infections.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.